Acasti Pharma Inc
XTSX:ACST
Acasti Pharma Inc
XTSX:ACST
Price:
0.58
CAD
1.75%
Market Closed
Market Cap:
CA$25.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Acasti Pharma Inc
XTSX:ACST
|
CA |
|
Griffon Corp
NYSE:GFF
|
US |
|
P
|
Parker-Hannifin Corp
LSE:0KFZ
|
US |
|
Frontier Services Group Ltd
HKEX:500
|
HK |
|
T
|
Tazmo Co Ltd
TSE:6266
|
JP |
|
Garnet International Ltd
BSE:512493
|
IN |
|
Builders FirstSource Inc
NYSE:BLDR
|
US |
|
Raymond Ltd
NSE:RAYMOND
|
IN |
|
Sac's Bar Holdings Inc
TSE:9990
|
JP |
|
Novocure Ltd
NASDAQ:NVCR
|
JE |
|
Snow Peak Inc
TSE:7816
|
JP |
|
Anhui Jianghuai Automobile Group Corp Ltd
SSE:600418
|
CN |
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
SG |
|
Lithium Americas Corp
TSX:LAC
|
CA |
|
Triple Flag Precious Metals Corp
TSX:TFPM
|
CA |
|
Van Elle Holdings PLC
LSE:VANL
|
UK |
|
Sheetal Diamonds Ltd
BSE:530525
|
IN |
|
A
|
Attica Holdings SA
ATHEX:ATTICA
|
GR |
|
C
|
Chuan Hup Holdings Ltd
SGX:C33
|
SG |
Relative Value
There is not enough data to reliably calculate the relative value of ACST.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ACST
Relative Value
Base Case
Not Available
Multiples Across Competitors
ACST Competitors Multiples
Acasti Pharma Inc Competitors
Acasti Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Acasti Pharma Inc
XTSX:ACST
|
25.9m CAD | 0 | -0.4 | 0.2 | 0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
860.3B USD | 13.2 | 41.7 | 28.1 | 30 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.9B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.8 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP | 4.9 | 28 | 15.5 | 21.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.3B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5.1 | 20.5 | 12.7 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
114.7B USD | 2.4 | 16.3 | 6.9 | 8.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
